QBIO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:32):

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies...

Stats
今日成交量	1 123.00
平均成交量	23 222.00
市值	29 019.00
EPS	$0 ( 2024-03-13 )
下一个收益日期	( $0 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-26	Corin Denis	Buy	200 000	Common Stock
2021-02-01	Rosenstadt William S	Buy	35 000	Common stock
2020-10-27	Corin Denis	Buy	500 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options

INSIDER POWER
100.00
Last 100 transactions
Buy: 7 488 702 \| Sell: 150 251

Q BioMed Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Q BioMed Inc. 财务报表

Annual	2022
营收:	$284 352
毛利润:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2022
营收:	$284 352
毛利润:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2021
营收:	$195 597
毛利润:	$-51 249.00 (-26.20 %)
EPS:	$-0.298

FY	2020
营收:	$30 000.00
毛利润:	$-296 009 (-986.70 %)
EPS:	$-0.650

Financial Reports:

No articles found.

Q BioMed Inc.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.